Astrazeneca PLC 6-K, filed Feb 27, 2020
Astrazeneca PLC (AZN)
6-K
2020-02-27
For: 2020-02-27
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on February 27, 2020.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
27 February 2020 07:00 GMT
TRANSACTION BY PERSON DISCHARGING MANAGERIAL
RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse
Regulation
AstraZeneca PLC (the Company) announces that, on 26 February
2020, it was notified by Tony Mok, a Non-Executive Director of
the Company, that, on 26 February 2020, Mr Mok purchased 1,000 of
the Company's American Depositary Shares (ADSs) at a price of
$48.00 per ADS. Two ADSs are equivalent to one Ordinary Share of
$0.25 in the Company.
The attached notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further
detail.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
|
a)
|
Name
|
Tony
Mok
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Non-Executive
Director
|
|
|
b)
|
Initial notification/Amendment
|
Initial
notification
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
AstraZeneca
PLC
|
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
|
|
|
b)
|
Nature of the transaction
|
Purchase
of AstraZeneca PLC American Depositary Shares
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
US$48.00
|
1,000
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
|
e)
|
Date of the transaction
|
26
February 2020
|
|
|
f)
|
Place of the transaction
|
NYSE
|
|
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
|
Media
Relations
|
|
|
|
Gonzalo
Viña
|
|
+44 203
749 5916
|
|
Rob
Skelding
|
Oncology
|
+44 203
749 5821
|
|
Rebecca
Einhorn
|
Oncology
|
+1 301
518 4122
|
|
Matt
Kent
|
BioPharmaceuticals
|
+44 203
749 5906
|
|
Angela
Fiorin
|
BioPharmaceuticals
|
+44
1223 344 690
|
|
Jennifer
Hursit
|
Other
|
+44
203 749 5762
|
|
Christina Malmberg
Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
Investor
Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Christer
Gruvris
|
BioPharmaceuticals
(Cardiovascular,
Metabolism)
|
+44 203
749 5711
|
|
Nick
Stone
|
BioPharmaceuticals
(Renal) Environmental, Social and Governance
|
+44 203
749 5716
|
|
Josie
Afolabi
|
BioPharmaceuticals
(Respiratory)
|
+44 203
749 5631
|
|
Tom
Waldron
|
Other
medicines
|
+44
7385 033 717
|
|
Craig
Marks
|
Finance
Fixed
income
|
+44
7881 615 764
|
|
Jennifer
Kretzmann
|
Corporate
access
Retail
investors
|
+44 203
749 5824
|
|
US
toll-free
|
|
+1 866
381 72 77
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
27 February
2020
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|